Galectin Therapeutics (GALT) Total Non-Current Liabilities (2010 - 2026)

Galectin Therapeutics' Total Non-Current Liabilities history runs 17 years deep, the most recent figure standing at $143.0 million for Q1 2026.

• In Q1 2026, Total Non-Current Liabilities rose 17.56% year-over-year to $143.0 million; the TTM figure through Mar 2026 stood at $143.0 million (up 17.56% YoY), while the FY2025 annual figure was $141.8 million, up 17.63% from the prior year.
• Total Non-Current Liabilities was $143.0 million for Q1 2026 at Galectin Therapeutics, up from $141.8 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $143.0 million in Q1 2026 to a low of $39.6 million in Q1 2022.
• Historically, Total Non-Current Liabilities has averaged $93.5 million across 5 years, with a median of $96.7 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Total Non-Current Liabilities surged 749.67% in 2022, then rose 13.24% in 2025.
• A 5-year view of Total Non-Current Liabilities shows it stood at $53.3 million in 2022, then jumped by 65.28% to $88.0 million in 2023, then soared by 36.89% to $120.5 million in 2024, then rose by 17.63% to $141.8 million in 2025, then grew by 0.88% to $143.0 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $143.0 million (Q1 2026), $141.8 million (Q4 2025), and $136.4 million (Q3 2025), per Business Quant data.